BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Madonna R, Cocco N, De Caterina R. Pathways and Drugs in Pulmonary Arterial Hypertension – Focus on the Role of Endothelin Receptor Antagonists. Cardiovasc Drugs Ther 2015;29:469-79. [DOI: 10.1007/s10557-015-6605-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Madonna R, De Caterina R, Geng YJ. Aerobic exercise-related attenuation of arterial pulmonary hypertension: A right arrow targets the disease? Vascul Pharmacol 2016;87:6-9. [PMID: 27720893 DOI: 10.1016/j.vph.2016.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Duan X, Li J, Chen L, Shi Y, Chen X, Xue T, Liu C, Wang X, Qiu Q, Yu Z, Qiang B, Wu H, Wu T, Zhang L, Chen Z, Jigme D, Xu A, Mima Z, Da Z, Ren M, Gesang D, Pubu Z, Li C, Lv Y, Zhou H, Zhang X, Dawa Z, Gongjue W, Wang L, Wu L, Li X. Surfactant Therapy for Respiratory Distress Syndrome in High- and Ultra-High-Altitude Settings. Front Pediatr 2022;10:777360. [DOI: 10.3389/fped.2022.777360] [Reference Citation Analysis]
3 Madonna R, De Caterina R, Geng YJ. Epigenetic regulation of insulin-like growth factor signaling: A novel insight into the pathophysiology of neonatal pulmonary hypertension. Vascul Pharmacol 2015;73:4-7. [PMID: 26254106 DOI: 10.1016/j.vph.2015.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
4 Pepke-zaba J, Ghofrani H, Hoeper MM. Medical management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017;26:160107. [DOI: 10.1183/16000617.0107-2016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
5 Lopez-Crisosto C, Arias-Carrasco R, Sepulveda P, Garrido-Olivares L, Maracaja-Coutinho V, Verdejo HE, Castro PF, Lavandero S. Novel molecular insights and public omics data in pulmonary hypertension. Biochim Biophys Acta Mol Basis Dis 2021;1867:166200. [PMID: 34144090 DOI: 10.1016/j.bbadis.2021.166200] [Reference Citation Analysis]
6 Ye W, Guo H, Xu J, Cai S, He Y, Shui X, Huang S, Luo H, Lei W. Heart‑lung crosstalk in pulmonary arterial hypertension following myocardial infarction (Review). Int J Mol Med 2020;46:913-24. [PMID: 32582962 DOI: 10.3892/ijmm.2020.4650] [Reference Citation Analysis]
7 Sergi C, Shen F, Lim DW, Liu W, Zhang M, Chiu B, Anand V, Sun Z. Cardiovascular dysfunction in sepsis at the dawn of emerging mediators. Biomed Pharmacother 2017;95:153-60. [PMID: 28841455 DOI: 10.1016/j.biopha.2017.08.066] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
8 Ruaro B, Baratella E, Caforio G, Confalonieri P, Wade B, Marrocchio C, Geri P, Pozzan R, Andrisano AG, Cova MA, Cortale M, Confalonieri M, Salton F. Chronic Thromboembolic Pulmonary Hypertension: An Update. Diagnostics 2022;12:235. [DOI: 10.3390/diagnostics12020235] [Reference Citation Analysis]
9 Zhang J, Lu X, Liu M, Fan H, Zheng H, Zhang S, Rahman N, Wołczyński S, Kretowski A, Li X. Melatonin inhibits inflammasome-associated activation of endothelium and macrophages attenuating pulmonary arterial hypertension. Cardiovasc Res 2020;116:2156-69. [PMID: 31774487 DOI: 10.1093/cvr/cvz312] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
10 Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2021;3:CD004434. [PMID: 33765691 DOI: 10.1002/14651858.CD004434.pub6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cunningham KP, Clapp LH, Mathie A, Veale EL. The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels. Front Pharmacol 2021;12:705421. [PMID: 34267666 DOI: 10.3389/fphar.2021.705421] [Reference Citation Analysis]
12 Xu T, Liu S, Ma T, Jia Z, Zhang Z, Wang A. Aldehyde dehydrogenase 2 protects against oxidative stress associated with pulmonary arterial hypertension. Redox Biol 2017;11:286-96. [PMID: 28030785 DOI: 10.1016/j.redox.2016.12.019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
13 Pesavento R, Prandoni P. Prevention and treatment of the chronic thromboembolic pulmonary hypertension. Thromb Res 2018;164:150-6. [PMID: 29526325 DOI: 10.1016/j.thromres.2018.02.149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Polverino F, Celli BR, Owen CA. COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? Pulm Circ. 2018;8:2045894018758528. [PMID: 29468936 DOI: 10.1177/2045894018758528] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
15 Verlinden NJ, Benza RL, Raina A. Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension. Pulm Circ 2020;10:2045894020945523. [PMID: 33354314 DOI: 10.1177/2045894020945523] [Reference Citation Analysis]